Canada to allow entry to those vaccinated with Sinopharm, Sinovac, Covaxin

Currently, Canada only accepts travellers who have received the vaccines, including Pfizer, Moderna, AstraZeneca and Johnson and Johnson

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Travellers who are fully vaccinated with the shots from Sinopharm, Sinovac and Covaxin will be allowed to enter Canada starting November 30
IANS Ottawa
2 min read Last Updated : Nov 20 2021 | 11:49 AM IST

Travellers who are fully vaccinated with the shots from Sinopharm, Sinovac and Covaxin will be allowed to enter Canada starting November 30, the Canadian government said.

Currently, Canada only accepts travellers who have received the vaccines, including Pfizer, Moderna, AstraZeneca and Johnson and Johnson.

Also starting November 30, people leaving Canada by land or by air for less than 72 hours will no longer be required to provide proof of a negative molecular test to re-enter the country, Xinhua news agency reported.

This change applies only to Canadians, permanent residents and individuals registered under the Indian Act, as well as accompanying children under 12, and individuals with medical contraindications to vaccination.

Additionally, starting January 15, certain groups of travellers, who are currently exempt from entry requirements, will only be allowed to enter Canada if they are fully vaccinated.

Those groups include individuals travelling to reunite with family, international students, professional and amateur athletes, individuals with a valid work permit and other essential service workers including truck drivers.

"With more Canadians getting vaccinated every day, we can move forward cautiously toward a more open border economy and society," said Health Minister Jean-Yves Duclos. "At the same time, we can't let our guard down."

To date, the country has reported a total of 1,762,434 cases with 29,481 deaths, according to the Canadian government.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCanadaPfizer

First Published: Nov 20 2021 | 11:49 AM IST

Next Story